Tecentriq(atezolizumab)

Tecentriq (atezolizumab) is indicated for the treatment of patients with metastatic non-small cell lung cancer who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving TECENTRIQ. The drug received accelerated approval and a Breakthrough Therapy designation in January 2015.

In clinical trials, Tecentriq demonstrated a confirmed objective response rate (ORR) of 14.8% (95% CI: 11.1%, 19.3%) across all patients. The median duration of response (DOR) in responders was not reached. For overall survival, Tecentriq showed a median of 12.6 months compared to 9.7 months for docetaxel, with an overall survival hazard ratio of 0.69. In another study, median overall survival for Tecentriq was 13.8 months versus 9.6 months for docetaxel.

Regarding safety, Grade 3 or 4 adverse events (AEs) occurred in 40.1% of atezolizumab patients, while treatment-related Grade 3 or 4 AEs were 11.3%. Serious adverse events (SAEs) were reported in 35.2% of atezolizumab patients. Grade 5 AEs (deaths) were 4.2% for atezolizumab and 3.7% for docetaxel, with treatment-related Grade 5 AEs at 0.7% for atezolizumab and 2.2% for docetaxel.